Results of intensive long-term treatment of familial hypercholesterolemia

American Journal of Cardiology

Volumn 78, Issue 12, 1996, Pages 1369-1374

  Retterstøl, Kjetil ^a   Stugaard, Marie ^a   Gørbitz, Christine ^a   Ose, Leiv ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CHOLESTEROL; COLESTYRAMINE; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PROBUCOL;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ATRIAL NATRIURETIC FACTOR; CHOLESTEROL; CHOLESTYRAMINE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LOVASTATIN; MALE; MIDDLE AGED; PROBUCOL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0030589266     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00649-2     Document Type: Article

References (30)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
2. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimes. JAMA 1990;264:3007-3012.
3. Goldman L, Goldman PA, Williams LW, Weinstein MC. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol 1993;72:75D-79D.
4. Williams RR, Hamilton-Craig I, Kostner GM, Hegele RA, Hayden MR, Pimstone SN, Faergman O, Schuster H, Steinhagen-Thiessen E, Beisiegel U, Keller C, Czeizel AE et al. In: Berg K, Boulyjenkov V, Christen Y eds. Genetic Approaches to Noncommunicable Diseases. Berlin Heidelberg: Springer-Verlag, 1996:35-45.
5. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
6. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
7. Hall C, Roleau JL, Moye L, de Champlain J, Bichet D, Sussex B, Packer M, Roulea J, Arnold MO. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994;89:1934-1942.
8. Lerman A, Gibbons RJ, Rodelheffer RJ, Bailey KR, McKinley LJ, Heublein DM, Burnett JC Jr. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993;341:1105-1109.
9. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, vol III. New York: Mc Graw-Hill. 1994;1981-2030.
10. Stugaard M, Wiig I, Ose L, Nordseth J,. Familial hypercholesterolemia. Intensive diet therapy combined with drug therapy. Tidsskr Nor Laegeforen 1992;112:2642-2646.
11. Hackett TP, Cassem NH. Psychologic aspects of rehabilitation following myocardial infarction. In: Wenger NK, Hellerstein HK eds. Rehabilitation of the Coronary Patient. New York:Wiley & Sons, 1978:243-253.
12. American Heart Association. Recommandation for the treatment of hypercholesterolemia. Circulation 1986;69:1065A-1090A.
13. Mourn T, Sørensen T, Næss S, Holmen J. Changes in quality of life caused by being diagnosed as hypertensive or other events in life. Tidsskr Nor Laegeforen 1992;112:18-23.
14. Malt UF, Mogstad TE, Refnin IB. Goldbergs general health questionnaire. Tidsskr Nor Laegeforen 1989;109:1391-1394.
15. Huppert FA, Walters DE, Day NE, Elliot BJ. The factor structure of the general health questionnaire (Goldgergs general health questionnaire-30). A reliability study on 6317 community residents. Br J Psychiatry 1989; 155:178-185.
16. Friedewal WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultrasentrifuge. Clin Chem 1972;18:499-502.
17. Sundsfjord JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentration of the N-terminal fragment of proatrial natriuretic factor in man. J Clin Endocrinol Metab 1988;66:605-610.
18. Keys A, Anderson JT, Grande F. Prediction of serum-cholesterol respons of man to changes in fats in the diet. Lancet 1957;2:959-966.
19. Dahlen GH. Lp(a) lipoprotein in cardiovasculer disease. Atherosclerosis 1994;108:11-26.
20. Rolland Cachera MF, Cole TJ, Sempe M, Tichet J, Rossignol C, Charraud A. Body mass index variations: centiles from birth to 87 years. Eur J Clin Nutr 1991;45:13-21.
21. Casey V, Dwyer JT, Coleman AK, Valadin I. Body mass index from childhood to middle age: a 50-y follow-up. Am J Clin Nutr 1992;56:14-18.
22. Gotto AM. Overview of current issues in management of dyslipidemia. Am J Cardiol 1993;71:3B-8B.
23. Downs JR, Oster G, Santanello NC. HMG-CoA reductase inhibitors and quality of life. JAMA 1993;269:3107-3108.
24. Tibben, A, Frets PG. Van de Kamp JJ, Niermeijer MF, Vegtervan der Vlis M, Roos RA, Rooymans HG, van Ommen GJ, Verhage F. On attitudes and appreciation 6 months after predicting DNA testing for Huntington disease in the Dutch program. Am J Med Genet 1993;48:103-111.
25. Lovastatin Study Group I Trough IV. Lovastatin 5-year safety and efficiacy study Arch Intern Med 1993;153:1079-1087.
26. International Task Force for Prevention of Coronary Heart Disease. Prevention of coronary heart disease: scientific background and new clinical guidlines. Recommandations of the European Atherosclerosis Society. Nutr Metab Cardiovasc Dis 1992;2:113-156.
27. Folkers, K. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Sci USA 1990;87:8931-8934.
28. Nohl H, Jordan W, Yongman RJ. Quinones in biology, functiones in electron transfer and oxygen activation. Adv Free Rad Biol Med 1986;2:211-279.
29. Greenberg S, Frishman WH, Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30: 596-608.
30. Laaksonen R, Ojala JP, Tikkanen MJ, Himberg JJ. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994;46:313-317.